ACS Publications. Most Trusted. Most Cited. Most Read
My Activity
CONTENT TYPES

Figure 1Loading Img

Analysis of Human Cytochrome P450 2C8 Substrate Specificity Using a Substrate Pharmacophore and Site-Directed Mutants

View Author Information
Laboratoire de Chimie et Biochimie Pharmacologiques et Toxicologiques, UMR 8601 CNRS, Université Paris 5, 45 Rue des Saints-Pères, 75270 Paris Cedex 06, France, and Department of Molecular and Experimental Medicine, The Scripps Research Institute, 10550 North Torrey Pines Road, MEM-255, La Jolla, California 92037
Cite this: Biochemistry 2004, 43, 49, 15379–15392
Publication Date (Web):November 18, 2004
https://doi.org/10.1021/bi0489309
Copyright © 2004 American Chemical Society

    Article Views

    731

    Altmetric

    -

    Citations

    LEARN ABOUT THESE METRICS
    Other access options

    Abstract

    Abstract Image

    The structural determinants of substrate specificity of human liver cytochrome P450 2C8 (CYP2C8) were investigated using site-directed mutants chosen on the basis of a preliminary substrate pharmacophore and a three-dimensional (3D) model. Analysis of the structural features common to CYP2C8 substrates exhibiting a micromolar Km led to a substrate pharmacophore in which the site of oxidation by CYP2C8 is 12.9, 8.6, 4.4, and 3.9 Å from features that could establish ionic or hydrogen bonds, and hydrophobic interactions with protein amino acid residues. Comparison of this pharmacophore with a 3D model of CYP2C8 constructed using the X-ray structure of CYP2C5 suggested potential CYP2C8 amino acid residues that could be involved in substrate recognition. Twenty CYP2C8 site-directed mutants were constructed and expressed in yeast to compare their catalytic activities using five CYP2C8 substrates that exhibit different structures and sizes [paclitaxel, fluvastatin, retinoic acid, a sulfaphenazole derivative (DMZ), and diclofenac]. Mutation of arginine 241 had marked effects on the hydroxylation of anionic substrates of CYP2C8 such as retinoic acid and fluvastatin. Serine 100 appears to be involved in hydrogen bonding interactions with a polar site of the CYP2C8 substrate pharmacophore, as shown by the 3−4-fold increase in the Km of paclitaxel and DMZ hydroxylation after the S100A mutation. Residues 114, 201, and 205 are predicted to be in close contact with substrates, and their mutations lead either to favorable hydrophobic interactions or to steric clashes with substrates. For instance, the S114F mutant was unable to catalyze the 6α-hydroxylation of paclitaxel. The S114F and F205A mutants were the best catalysts for retinoic acid and paclitaxel (or fluvastatin) hydroxylation, respectively, with kcat/Km values 5 and 2.1 (or 2.4) times higher, respectively, than those found for CYP2C8. Preliminary experiments of docking of the substrate into the experimentally determined X-ray structure of substrate-free CYP2C8, which became available quite recently [Schoch, G. A., et al. (2004) J. Biol. Chem. 279, 9497], were consistent with key roles for S100, S114, and F205 residues in substrate binding. The results suggest that the effects of mutation of arginine 241 on anionic substrate hydroxylation could be indirect and result from alterations of the packing of helix G with helix B‘.

    Read this article

    To access this article, please review the available access options below.

    Get instant access

    Purchase Access

    Read this article for 48 hours. Check out below using your ACS ID or as a guest.

    Recommended

    Access through Your Institution

    You may have access to this article through your institution.

    Your institution does not have access to this content. You can change your affiliated institution below.

     The research was supported by funds from CNRS and Ministry of Research (France) (group of D.M.) and by the U.S. National Institutes of Health (Grant GM031001, group of E.F.J.).

     UMR 8601 CNRS.

    §

     The Scripps Research Institute.

    *

     To whom correspondence should be addressed. Telephone: 33 1 42 86 21 69. Fax:  33 1 42 86 83 87. E-mail:  daniel.mansuy@ univ-paris5.fr.

    Cited By

    This article is cited by 39 publications.

    1. Brian S. Safina, Steven J. McKerrall, Shaoyi Sun, Chien-An Chen, Sultan Chowdhury, Qi Jia, Jun Li, Alla Y. Zenova, Jean-Christophe Andrez, Girish Bankar, Philippe Bergeron, Jae H. Chang, Elaine Chang, Jun Chen, Richard Dean, Shannon M. Decker, Antonio DiPasquale, Thilo Focken, Ivan Hemeon, Kuldip Khakh, Amy Kim, Rainbow Kwan, Andrea Lindgren, Sophia Lin, Jonathan Maher, Janette Mezeyova, Dinah Misner, Karen Nelkenbrecher, Jodie Pang, Rebecca Reese, Shannon D. Shields, Luis Sojo, Tao Sheng, Henry Verschoof, Matthew Waldbrook, Michael S. Wilson, Zhiwei Xie, Clint Young, Tanja S. Zabka, David H. Hackos, Daniel F. Ortwine, Andrew D. White, J.P. Johnson, Jr., C. Lee Robinette, Christoph M. Dehnhardt, Charles J. Cohen, Daniel P. Sutherlin. Discovery of Acyl-sulfonamide Nav1.7 Inhibitors GDC-0276 and GDC-0310. Journal of Medicinal Chemistry 2021, 64 (6) , 2953-2966. https://doi.org/10.1021/acs.jmedchem.1c00049
    2. Yong Ma, Yue Fu, S. Cyrus Khojasteh, Deepak Dalvie, and Donglu Zhang . Glucuronides as Potential Anionic Substrates of Human Cytochrome P450 2C8 (CYP2C8). Journal of Medicinal Chemistry 2017, 60 (21) , 8691-8705. https://doi.org/10.1021/acs.jmedchem.7b00510
    3. Jed Zaretzki, Patrik Rydberg, Charles Bergeron, Kristin P. Bennett, Lars Olsen, and Curt M. Breneman . RS-Predictor Models Augmented with SMARTCyp Reactivities: Robust Metabolic Regioselectivity Predictions for Nine CYP Isozymes. Journal of Chemical Information and Modeling 2012, 52 (6) , 1637-1659. https://doi.org/10.1021/ci300009z
    4. Yasuhiro Uno, Norie Murayama, Hiroshi Yamazaki. Novel Cytochrome P450 2C119 Enzymes in Cynomolgus and Rhesus Macaques Metabolize Progesterone, Diclofenac, and Omeprazole. Drug Metabolism and Disposition 2024, 52 (3) , 266-273. https://doi.org/10.1124/dmd.123.001583
    5. Yoo-Bin Lee, Vitchan Kim, Sung-Gyu Lee, Gyu-Hyeong Lee, Changmin Kim, Eunseo Jeong, Donghak Kim. Functional Characterization of Allelic Variations of Human Cytochrome P450 2C8 (V181I, I244V, I331T, and L361F). International Journal of Molecular Sciences 2023, 24 (9) , 8032. https://doi.org/10.3390/ijms24098032
    6. Manish B. Shah. Inhibition of CYP2C8 by Acyl Glucuronides of Gemfibrozil and Clopidogrel: Pharmacological Significance, Progress and Challenges. Biomolecules 2022, 12 (9) , 1218. https://doi.org/10.3390/biom12091218
    7. Daigo Asano, Syoya Hamaue, Hamim Zahir, Hideyuki Shiozawa, Yumi Nishiya, Takako Kimura, Miho Kazui, Naotoshi Yamamura, Marie Ikeguchi, Takahiro Shibayama, Shin-ichi Inoue, Tsuyoshi Shinozuka, Toshiyuki Watanabe, Chizuko Yahara, Nobuaki Watanabe, Kouichi Yoshinari. CYP2C8-Mediated Formation of a Human Disproportionate Metabolite of the Selective Na V 1.7 Inhibitor DS-1971a, a Mixed Cytochrome P450 and Aldehyde Oxidase Substrate. Drug Metabolism and Disposition 2022, 50 (3) , 235-242. https://doi.org/10.1124/dmd.121.000665
    8. Dongfang Ma, Xuan-Yu Meng, David R. Bell, Shengtang Liu, Ruhong Zhou. Inhibition of CYP2C8 by metallofullerenol Gd@C82(OH)22 through blocking substrate channels and substrate recognition sites. Carbon 2018, 127 , 667-675. https://doi.org/10.1016/j.carbon.2017.10.080
    9. Barry C. Jones, Roshini Markandu, Chungang Gu, Graeme Scarfe. CYP-Mediated Sulfoximine Deimination of AZD6738. Drug Metabolism and Disposition 2017, 45 (11) , 1133-1138. https://doi.org/10.1124/dmd.117.077776
    10. Robert S. Foti, Philippe Diaz, Dominique Douguet. Comparison of the ligand binding site of CYP2C8 with CYP26A1 and CYP26B1: a structural basis for the identification of new inhibitors of the retinoic acid hydroxylases. Journal of Enzyme Inhibition and Medicinal Chemistry 2016, 31 (sup2) , 148-161. https://doi.org/10.1080/14756366.2016.1193734
    11. Janne T. Backman, Anne M. Filppula, Mikko Niemi, Pertti J. Neuvonen, . Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions. Pharmacological Reviews 2016, 68 (1) , 168-241. https://doi.org/10.1124/pr.115.011411
    12. Łukasz Gricman, Constantin Vogel, Jürgen Pleiss. Identification of universal selectivity‐determining positions in cytochrome P450 monooxygenases by systematic sequence‐based literature mining. Proteins: Structure, Function, and Bioinformatics 2015, 83 (9) , 1593-1603. https://doi.org/10.1002/prot.24840
    13. James B.Y.H. Behrendorff, Weiliang Huang, Elizabeth M.J. Gillam. Directed evolution of cytochrome P450 enzymes for biocatalysis: exploiting the catalytic versatility of enzymes with relaxed substrate specificity. Biochemical Journal 2015, 467 (1) , 1-15. https://doi.org/10.1042/BJ20141493
    14. Andrew G. Leach, Nathan J. Kidley. Cytochrome P450 Substrate Recognition and Binding. 2014, 103-132. https://doi.org/10.1002/9783527673261.ch05
    15. Daniel R. Albaugh, Michael B. Fisher. Major Human Conjugative Drug‐Metabolizing Enzymes. 2014, 1-35. https://doi.org/10.1002/9781118541203.xen0013
    16. XIAO-XI LI, JI-LONG ZHANG, QING-CHUAN ZHENG, YING-LU CUI, RUI-JUAN NIU, HONG-XING ZHANG, CHIA-CHUNG SUN. CATALYTIC MECHANISM OF ALL- TRANS -RETINOIC ACID 4-HYDROXYLATION MEDIATED BY CYTOCHROME P450 2C8: HOW DOES ARGININE 241 AFFECT THE C – H BOND ACTIVATION?. Journal of Theoretical and Computational Chemistry 2013, 12 (08) , 1341009. https://doi.org/10.1142/S0219633613410095
    17. Francesco Rua, Giovanna Di Nardo, Sheila J. Sadeghi, Gianfranco Gilardi. Toward reduction in animal sacrifice for drugs: Molecular modeling of Macaca fascicularis P450 2C20 for virtual screening of Homo sapiens P450 2C8 substrates. Biotechnology and Applied Biochemistry 2012, 59 (6) , 479-489. https://doi.org/10.1002/bab.1051
    18. Upendra A. Argikar. Unusual Glucuronides. Drug Metabolism and Disposition 2012, 40 (7) , 1239-1251. https://doi.org/10.1124/dmd.112.045096
    19. Dong Dong, Baojian Wu, Diana Chow, Ming Hu. Substrate selectivity of drug-metabolizing cytochrome P450s predicted from crystal structures and in silico modeling. Drug Metabolism Reviews 2012, 44 (2) , 192-208. https://doi.org/10.3109/03602532.2011.645580
    20. Mitsuhiro Nishihara, Miyako Sudo, Naohiro Kawaguchi, Junzo Takahashi, Yutaka Kiyota, Takahiro Kondo, Satoru Asahi. An Unusual Metabolic Pathway of Sipoglitazar, a Novel Antidiabetic Agent: Cytochrome P450-Catalyzed Oxidation of Sipoglitazar Acyl Glucuronide. Drug Metabolism and Disposition 2012, 40 (2) , 249-258. https://doi.org/10.1124/dmd.111.040105
    21. Dong Dong, Baojian Wu. Substrate selectivity of drug-metabolizing cytochrome P450s predicted from crystal structures and in silico modeling. Drug Metabolism Reviews 2012, 44 (1) , 1-17. https://doi.org/10.3109/03602532.2011.645581
    22. Robert S. Foti, Michael B. Fisher. UDP ‐Glucuronosyltransferases: Pharmacogenetics, Functional Characterization, and Clinical Relevance. 2012, 1-71. https://doi.org/10.1002/9780470921920.edm015
    23. Noelia Nebot, Severine Crettol, Fabrizio D'Esposito, Bruce Tattam, David E Hibbs, Michael Murray. Participation of CYP2C8 and CYP3A4 in the N‐demethylation of imatinib in human hepatic microsomes. British Journal of Pharmacology 2010, 161 (5) , 1059-1069. https://doi.org/10.1111/j.1476-5381.2010.00946.x
    24. Sean C Gay, Arthur G Roberts, James R Halpert. Structural Features of Cytochromes P450 and Ligands that Affect Drug Metabolism as Revealed by X-Ray Crystallography and NMR. Future Medicinal Chemistry 2010, 2 (9) , 1451-1468. https://doi.org/10.4155/fmc.10.229
    25. Yiwen Gao, Duan Liu, Huijuan Wang, Juanli Zhu, Chao Chen. Functional characterization of five CYP2C8 variants and prediction of CYP2C8 genotype-dependent effects on in vitro and in vivo drug–drug interactions. Xenobiotica 2010, 40 (7) , 467-475. https://doi.org/10.3109/00498254.2010.487163
    26. Nobumitsu Hanioka, Kimiaki Matsumoto, Yoshiro Saito, Shizuo Narimatsu. Functional Characterization of CYP2C8.13 and CYP2C8.14: Catalytic Activities toward Paclitaxel. Basic & Clinical Pharmacology & Toxicology 2010, 107 (1) , 565-569. https://doi.org/10.1111/j.1742-7843.2010.00543.x
    27. Lu Sun, Zhong-Hua Wang, Feng-Yun Ni, Xiang-Shi Tan, Zhong-Xian Huang. The Role of Ile476 in the Structural Stability and Substrate Binding of Human Cytochrome P450 2C8. The Protein Journal 2010, 29 (1) , 32-43. https://doi.org/10.1007/s10930-009-9218-8
    28. Y.-Y. Zhang, Y. Liu, J.-W. Zhang, G.-B. Ge, H.-X. Liu, L.-M. Wang, J. Sun, L. Yang. C-7 configuration as one of determinants in taxanes metabolism by human cytochrome P450 enzymes. Xenobiotica 2009, 39 (12) , 903-914. https://doi.org/10.3109/00498250903271989
    29. Barry C. Jones, Donald S. Middleton, Kuresh Youdim. 6 Cytochrome P450 Metabolism and Inhibition: Analysis for Drug Discovery. 2009, 239-263. https://doi.org/10.1016/S0079-6468(08)00206-3
    30. Guillaume A. Schoch, Jason K. Yano, Stefaan Sansen, Patrick M. Dansette, C. David Stout, Eric F. Johnson. Determinants of Cytochrome P450 2C8 Substrate Binding. Journal of Biological Chemistry 2008, 283 (25) , 17227-17237. https://doi.org/10.1074/jbc.M802180200
    31. Rajinder Singh, Jonathan G. Ting, Yan Pan, Lay Kek Teh, Rusli Ismail, Chin Eng Ong. Functional Role of Ile264 in CYP2C8: Mutations Affect Haem Incorporation and Catalytic Activity. Drug Metabolism and Pharmacokinetics 2008, 23 (3) , 165-174. https://doi.org/10.2133/dmpk.23.165
    32. Tímea Polgár, Dóra K. Menyhárd, György M. Keserű. Effective virtual screening protocol for CYP2C9 ligands using a screening site constructed from flurbiprofen and S-warfarin pockets. Journal of Computer-Aided Molecular Design 2007, 21 (9) , 539-548. https://doi.org/10.1007/s10822-007-9137-8
    33. Pierre Lafite, Sylvie Dijols, Darryl C. Zeldin, Patrick M. Dansette, Daniel Mansuy. Selective, competitive and mechanism-based inhibitors of human cytochrome P450 2J2. Archives of Biochemistry and Biophysics 2007, 464 (2) , 155-168. https://doi.org/10.1016/j.abb.2007.03.028
    34. Larry J. Jolivette, Sean Ekins. Methods for Predicting Human Drug Metabolism. 2007, 131-176. https://doi.org/10.1016/S0065-2423(06)43005-5
    35. Brian W. Ogilvie, Donglu Zhang, Wenying Li, A. David Rodrigues, Amy E. Gipson, Jeff Holsapple, Paul Toren, Andrew Parkinson. GLUCURONIDATION CONVERTS GEMFIBROZIL TO A POTENT, METABOLISM-DEPENDENT INHIBITOR OF CYP2C8: IMPLICATIONS FOR DRUG-DRUG INTERACTIONS. Drug Metabolism and Disposition 2006, 34 (1) , 191-197. https://doi.org/10.1124/dmd.105.007633
    36. Dijana Matak Vinkovič, Sheena Whyte, Harren Jhoti, Jose Cosme, Pamela A. Williams. Design, Development and Optimization: Crystal Structures of Microsomal Cytochromes P450. 2005, 1581-1602. https://doi.org/10.1002/9783527620982.ch66
    37. Karin Schleinkofer, Sudarko, Peter J Winn, Susanne K Lüdemann, Rebecca C Wade. Do mammalian cytochrome P450s show multiple ligand access pathways and ligand channelling?. EMBO reports 2005, 6 (6) , 584-589. https://doi.org/10.1038/sj.embor.7400420
    38. Hiroyuki Hichiya, Toshiko Tanaka-Kagawa, Akiko Soyama, Hideto Jinno, Satoru Koyano, Noriko Katori, Erika Matsushima, Shigehisa Uchiyama, Hiroshi Tokunaga, Hideo Kimura, Narihiro Minami, Masaaki Katoh, Kenji Sugai, Yu-ichi Goto, Tomohide Tamura, Noboru Yamamoto, Yuichiro Ohe, Hideo Kunitoh, Hiroshi Nokihara, Teruhiko Yoshida, Hironobu Minami, Nagahiro Saijo, Masanori Ando, Shogo Ozawa, Yoshiro Saito, Jun-ichi Sawada. FUNCTIONAL CHARACTERIZATION OF FIVE NOVEL CYP2C8 VARIANTS, G171S, R186X, R186G, K247R, AND K383N, FOUND IN A JAPANESE POPULATION. Drug Metabolism and Disposition 2005, 33 (5) , 630-636. https://doi.org/10.1124/dmd.105.003830
    39. M. Delaforge, A. Pruvost, L. Perrin, F. André. CYTOCHROME P450-MEDIATED OXIDATION OF GLUCURONIDE DERIVATIVES: EXAMPLE OF ESTRADIOL-17β-GLUCURONIDE OXIDATION TO 2-HYDROXY-ESTRADIOL-17β-GLUCURONIDE BY CYP 2C8. Drug Metabolism and Disposition 2005, 33 (3) , 466-473. https://doi.org/10.1124/dmd.104.002097

    Pair your accounts.

    Export articles to Mendeley

    Get article recommendations from ACS based on references in your Mendeley library.

    Pair your accounts.

    Export articles to Mendeley

    Get article recommendations from ACS based on references in your Mendeley library.

    You’ve supercharged your research process with ACS and Mendeley!

    STEP 1:
    Click to create an ACS ID

    Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

    Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

    Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

    MENDELEY PAIRING EXPIRED
    Your Mendeley pairing has expired. Please reconnect